Cover Image
市場調查報告書

抗感染劑的全球市場分析:各類型 (抗菌劑,頭孢菌素,青霉素,喹諾酮類,大環內酯類,碳青霉烯類,抗真菌劑,Azole,棘球白素,多烯,抗病毒藥物),市場區隔預測

Anti-infective Agents Market Analysis By Type (Antibacterial, Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems, Antifungal, Azoles, Echinocandins, Polyenes, Antiviral) And Segment Forecasts To 2024

出版商 Grand View Research, Inc. 商品編碼 368021
出版日期 內容資訊 英文 90 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
抗感染劑的全球市場分析:各類型 (抗菌劑,頭孢菌素,青霉素,喹諾酮類,大環內酯類,碳青霉烯類,抗真菌劑,Azole,棘球白素,多烯,抗病毒藥物),市場區隔預測 Anti-infective Agents Market Analysis By Type (Antibacterial, Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems, Antifungal, Azoles, Echinocandins, Polyenes, Antiviral) And Segment Forecasts To 2024
出版日期: 2016年07月31日 內容資訊: 英文 90 Pages
簡介

本報告提供全球抗感染劑市場相關調查,彙整產業預測,以及各類型,各地區趨勢,及打入市場的主要企業簡介等資料。

第1章 摘要整理

第2章 市場概要

第3章 市場變動,趨勢,範圍

  • 市場區隔和範圍
    • 推動市場的要素分析
  • 簡報及成長預測製圖
  • SWOT分析
  • 波特產業分析

第4章 各類型預測及趨勢分析

  • 各類型趨勢分析
  • 抗菌劑
    • 抗菌劑
    • 頭孢菌素
    • 青霉素
    • 喹諾酮類
    • 大環內酯類
    • 碳青霉烯類
    • 其他
  • 抗真菌劑
    • 抗真菌劑
    • Azole
    • 棘球白素
    • 多烯
  • 抗病毒藥物

第5章 各地區預測及趨勢分析

  • 各地區市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第6章 競爭環境

  • 策略性架構
  • 市場進入分類
  • 企業簡介
    • Pfizer Inc.
    • Abbott Laboratories
    • Gilead Sciences Inc.
    • Bristol- Myers Squibb & Co
    • Bayer Healthcare AG
    • AstraZeneca plc
    • Boehringer Ingelheim GmbH
    • Novartis AG
    • Sanofi Aventis S.A.
    • Johnson & Johnson Inc.
    • GlaxoSmithKline Plc

圖表

目錄

The global anti-infective agents market is expected to reach over USD 111.4 billion by 2024 according to a new report by Grand View Research, Inc. The rising prevalence of infectious diseases such as HIV, H1N1, and Ebola virus reflect the profound changes in behavioral patterns of communities over the recent decades. The societal changes and the increasing awareness levels amongst the healthcare professionals and the patients pertaining to these diseases are driving the anti-infective agents market.

Organizations, such as the WHO and CDC are actively involved in spreading awareness amongst people regarding the implications of infectious diseases, which are fatal in nature and the importance of early treatment. The CDC has collaborated with the National Health Ministry (NHM) in an attempt to spread awareness and enhance the treatment rates for communicable diseases in developing countries such as Brazil, China, Nigeria, and India.

However, the introduction of novel therapeutics with increased potency and efficacy and the commercialization of pipeline products, such as commercialization of Omadacycline in 2018 for the treatment of Community Acquired Bacterial Pneumonia (CABP) in the near future, are expected to favorthe market growth.

Further keyfindings from the study suggest:

The antibacterial segment was observed to account for the largest share of over 54.0% in 2015. The large market share is attributed to the fact that antibacterials are preferred as the first line of treatment for a large range of infections, the high prescription rates exhibited by this segment, and the increased accessibility of the antibacterials due to their over-the-counter status.

The development of combination drugs to treat and prevent, serious and life-threatening infections is expected to accentuate the usage of anti-infective drugs. For instance, in 2012, Gilead Sciences, Inc. launched Stribild, which is a comprehensive treatment regimen inclusive of four drugs(cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate) used for the treatment of HIV patients without prior retroviral treatment record.

The anti-viral agents segment is expected to grow at a swift CAGR of over 3.5% owing to the high price associated with the introduction of new potent anti-viral drugs such as Vicriviroc for HIV treatment purpose

North America dominated the overall anti-infective agents market in terms of revenue of over25.0 billion in 2015.The rise in prevalence of infectious diseases including hospital-acquired infections in both, children and adults, and the resultant overuse of antibiotics coupled with the increased accessibility to non-prescription anti-infectives in the market are the factors responsible for its dominance.

Asia Pacific is one of the fastest growing regional segments owing to the presence of high, unmet market demand for novel drugs, rapid improvements in healthcare infrastructure coupled with the rising awareness amongst healthcare professionals as well as patients

Some of the major companies operating in this market are Abbott Laboratories, Gilead Sciences, Inc., Bristol-Myers Squibb Co., Merck & Co., Inc, Bayer Healthcare AG, AstraZeneca Plc, Boehringer Ingelheim, and Novartis AG.

Effective disease management involves a range of long-term strategies such as new product development, merger and acquisitions, co-development, and expansion. For instance, in 2015, ReViral has received a funding of USD 21 million for the development of its RV521 drug by the Wellcome Trust.

Table of Contents

Chapter 1: Executive Summary

Chapter 2: Market Snapshot

Chapter 3: Market Variables, Trends & Scope

  • 3.1. Market segmentation & scope
    • 3.1.1. Market Driver Analysis
      • 3.1.1.1. Presence of favourable government initiatives
  • 3.2. Penetration & growth prospect mapping
  • 3.3. Anti-infective agents-SWOT Analysis, By Factor(political & legal, economic and technological)
  • 3.4. Industry Analysis-Porter's

Chapter 4: Market Categorization 1: Anti-infective agent Type Estimates & Trend Analysis

  • 4.1. Anti-infective agents market: type movement analysis
  • 4.2. Antibacterial
    • 4.2.1. Antibacterials market, 2013-2024(USD Million)
    • 4.2.2. Cephalosporins market, 2013-2024(USD Million)
    • 4.2.3. Penicillins market, 2013-2024(USD Million)
    • 4.2.4. Fluoroquinolones market, 2013-2024(USD Million)
    • 4.2.5. Macrolides market, 2013-2024(USD Million)
    • 4.2.6. Carbapenems market, 2013-2024(USD Million)
    • 4.2.7. Others market, 2013-2024(USD Million)
  • 4.3. Antifungal
    • 4.3.1. Antifungals market, 2013-2024(USD Million)
    • 4.3.2. Azoles market, 2013-2024(USD Million)
    • 4.3.3. Echinocandins market, 2013-2024(USD Million)
    • 4.3.4. Polyenes market, 2013-2024(USD Million)
  • 4.4. Antiviral
    • 4.4.1. Antivirals market, 2013-2024(USD Million)

Chapter 5: Market Categorization 3: Regional Estimates & Trend Analysis, by Type & Test

  • 5.1. Anti-infective agents market share by region, 2015 & 2024
  • 5.2. North America
    • 5.2.1. U.S.
    • 5.2.2. Canada
  • 5.3. Europe
    • 5.3.1. Germany
    • 5.3.2. UK
    • 5.3.3. France
  • 5.4. Asia Pacific
    • 5.4.1. Japan
    • 5.4.2. India
    • 5.4.3. China
  • 5.5. Latin America
    • 5.5.1. Brazil
    • 5.5.2. Mexico
  • 5.6. MEA
    • 5.6.1. South Africa

Chapter 6: Competitive Landscape

  • 6.1. Strategy framework
  • 6.2. Market participation categorization
  • 6.3. Company Profiles
    • 6.3.1. Pfizer Inc.
      • 6.3.1.1. Company Overview
      • 6.3.1.2. Financial Performance
      • 6.3.1.3. Product Benchmarking
      • 6.3.1.4. Strategic Initiatives
    • 6.3.2. Abbott Laboratories
      • 6.3.2.1. Company Overview
      • 6.3.2.2. Financial Performance
      • 6.3.2.3. Product Benchmarking
      • 6.3.2.4. Strategic Initiatives
    • 6.3.3. Gilead Sciences Inc.
      • 6.3.3.1. Company Overview
      • 6.3.3.2. Financial Performance
      • 6.3.3.3. Product Benchmarking
      • 6.3.3.4. Strategic Initiatives
    • 6.3.4. Bristol- Myers Squibb & Co
      • 6.3.4.1. Company Overview
      • 6.3.4.2. Financial Performance
      • 6.3.4.3. Product Benchmarking
      • 6.3.4.4. Strategic Initiatives
    • 6.3.5. Bayer Healthcare AG
      • 6.3.5.1. Company Overview
      • 6.3.5.2. Financial Performance
      • 6.3.5.3. Product Benchmarking
      • 6.3.5.4. Strategic Initiatives
    • 6.3.6. AstraZeneca plc
      • 6.3.6.1. Company Overview
      • 6.3.6.2. Financial Performance
      • 6.3.6.3. Product Benchmarking
      • 6.3.6.4. Strategic Initiatives
    • 6.3.7. Boehringer Ingelheim GmbH
      • 6.3.7.1. Company Overview
      • 6.3.7.2. Financial Performance
      • 6.3.7.3. Product Benchmarking
      • 6.3.7.4. Strategic Initiatives
    • 6.3.8. Novartis AG
      • 6.3.8.1. Company Overview
      • 6.3.8.2. Financial Performance
      • 6.3.8.3. Product Benchmarking
      • 6.3.8.4. Strategic Initiatives
    • 6.3.9. Sanofi Aventis S.A.
      • 6.3.9.1. Company Overview
      • 6.3.9.2. Financial Performance
      • 6.3.9.3. Product Benchmarking
      • 6.3.9.4. Strategic Initiatives
    • 6.3.10. Johnson & Johnson Inc.
      • 6.3.10.1. Company Overview
      • 6.3.10.2. Financial Performance
      • 6.3.10.3. Product Benchmarking
      • 6.3.10.4. Strategic Initiatives
    • 6.3.11. GlaxoSmithKline Plc
      • 6.3.11.1. Company Overview
      • 6.3.11.2. Financial Performance
      • 6.3.11.3. Product Benchmarking
      • 6.3.11.4. Strategic Initiatives

List of Tables

  • TABLE 1: Anti-infective Agents-Market Driver Analysis
  • TABLE 2: North America Anti-infective agents market, by type, 2013 - 2024 (USD Million)
  • TABLE 3: North America Antibacterials market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 4: North America Antifungals market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 5: U.S. Anti-infective agents market, by type, 2013 - 2024 (USD Million)
  • TABLE 6: U.S. Antibacterials market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 7: U.S. Antifungals market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 8: Canada Anti-infective agents market, by type, 2013 - 2024 (USD Million)
  • TABLE 9: Canada Antibacterials market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 10: Canada Antifungals market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 11: Europe Anti-infective agents market, by type, 2013 - 2024 (USD Million)
  • TABLE 12: Europe Antibacterials market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 13: Europe Antifungals market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 14: Germany Anti-infective agents market, by type, 2013 - 2024 (USD Million)
  • TABLE 15: Germany Antibacterials market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 16: Germany Antifungals market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 17: UK Anti-infective agents market, by type, 2013 - 2024 (USD Million)
  • TABLE 18: UK Antibacterial market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 19: UK Antifungal market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 20: France Anti-infective agents market, by type, 2013 - 2024 (USD Million)
  • TABLE 21: France Antibacterials market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 22: France Antifungals market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 23: Asia Pacific Anti-infective agents market, by type, 2013 - 2024 (USD Million)
  • TABLE 24: Asia Pacific Antibacterials market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 25: Asia Pacific Antifungals market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 26: Japan Anti-infective agents market, by type, 2013 - 2024 (USD Million)
  • TABLE 27: Japan Antibacterials market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 28: Japan Antifungals market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 29: India Anti-infective agents market, by type, 2013 - 2024 (USD Million)
  • TABLE 30: India Antibacterials market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 31: India Antifungals market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 32: China Anti-infective agents market, by type, 2013 - 2024 (USD Million)
  • TABLE 33: China Antibacterials market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 34: China Antifungals market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 35: Brazil Anti-infective agents market, by type, 2013 - 2024 (USD Million)
  • TABLE 36: Brazil Antibacterials market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 37: Brazil Antifungals market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 38: Mexico Anti-infective agents market, by type, 2013 - 2024 (USD Million)
  • TABLE 39: Mexico Antibacterials market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 40: Mexico Antifungals market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 41: MEA Anti-infective agents market, by type, 2013 - 2024 (USD Million)
  • TABLE 42: MEA Antibacterials market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 43: MEA Antifungals market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 44: South Africa Anti-infective agents market, by type, 2013 - 2024 (USD Million)
  • TABLE 45: South Africa Antibacterials market, by drug class, 2013 - 2024 (USD Million)
  • TABLE 46: South Africa Antifungals market, by drug class, 2013 - 2024 (USD Million)
Back to Top